Removing barriers between patients and treatments
Medications exist that could transform lives.
A treatment that could manage a chronic condition. A drug that could slow disease progression. A prescription that could change everything.
Yet barriers keep these medications from the patients who need them.
The barriers are specific: cost, prior authorization denials, pharmacy availability, and paperwork that most patients can’t navigate alone. Many patients leave a doctor’s office with a prescription they never fill. Not because they don’t want the medication. Because the system between the prescription pad and the pharmacy is broken.
The treatment exists. Access doesn’t.
We remove barriers between people and medications.
We identify specific obstacles, including cost, complexity, or systemic failure, and build solutions that improve access.
This isn’t advocacy from a distance. It’s operational work at the point where access breaks down.
We identify the specific barrier standing between a patient and their medication. Then we remove it. Sometimes that means connecting a patient to a manufacturer assistance program. Sometimes it means resolving a prior authorization denial. Sometimes it means simplifying a process no one has bothered to fix. This isn’t advocacy. It’s operational work at the exact point where access breaks down.
Understanding exactly what prevents patients from obtaining the medications they need: cost, insurance complexity, pharmacy availability, paperwork burden.
Creating pathways that address specific barriers, connecting patients to assistance programs, navigating insurance complexity, solving logistics problems.
Prescriptions filled. Treatments started. Conditions managed.
When barriers fall, treatments work. Conditions become manageable, health improves, and lives change.
Closing the gap between a prescription and the patient who needs it is among the highest-impact work in health access. It’s also among the least funded.
Fight Sarcoma demonstrates our model.
As we grow, we will expand into additional cancer types where access gaps cost lives.
The methodology works and the infrastructure scales. More patients can be connected to care.
